CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells
in treating patients with lymphoid malignancies that have spread to other places in the body
and usually cannot be cured or controlled with treatment. Sometimes researchers change the
deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells
that support the immune system) using a process called "gene transfer." Gene transfer
involves drawing blood from the patient, and then separating out the T-cells using a machine.
Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the
changed T-cells into the body of the patient. Injecting modified T-cells made from the
patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Intrexon Corporation National Cancer Institute (NCI) Ziopharm Ziopharm Oncology